



Faye Vazvaei-Smith, MS

Merck & Co. Inc.

Faye is currently Executive Director of the regulated PK Bioanalysis Group of Merck Research Laboratories, West Point, PA, USA. In this role, she leads the Regulated PK Bioanalytics group with overall responsibility for strategic and scientific oversight for method development, validation, and implementation of regulated bioanalytical assays to quantitate drug, metabolites, and anti-drug antibodies supporting small molecules, peptides, and biologics utilizing chromatographic-mass spectrometry and ligand binding assays. Before her recent promotion to Executive Director, Faye led the Clinical PK Bioanalytical team at Merck. Prior to joining Merck in April 2019, Faye was with Roche for seventeen years and held several positions rising from Lab Head to Global Head of Bioanalytical Outsourcing, and Bioanalytical Oncology Group Head in the Department of Clinical Pharmacology and Bioanalytical R&D. Faye is highly engaged within the global bioanalytical community through AAPS and IQ, and currently serves as the Member at Large on the AAPS Board of Directors. She also serves on the International Council of Harmonization Bioanalytical Method Validation (ICH M10) Expert Working Group as the BIO Organization Representative. Faye has a bachelor's degree in Chemical Engineering from Sharif University of Technology, Tehran, Iran and a master's degree in Biotechnology from Johns Hopkins University.